SUSTAINED RELEASE MICROPARTICULATE DELIVERY SYSTEM OF INTERFERON-α-2B. Microparticulate Drug Delivery For Ovarian Cancer

      Аннотация: The encapsulation mechanism of *rINF-α-2b in lipid, carbohydrate and protein based microspheres to achieve high encapsulation efficiency and protein loading capacity. *rINF-α-2b is a fragile molecule and encapsulation requires in addition the preservation of their structural integrity and functionality. We estimated that *rINF-α-2b-Pt-GMs-15 offered sustained release of protein over two weeks and released 95.01±4.23% of *rINF-α-2b. The stability study assessment by gel electrophoresis and circular dichroism confirmed post translation structural integrity of *rINF-α-2b in *rINF-α-2b-Pt-GMs-15 nanoformulation. In vitro therapeutic efficacy testing of optimized formulation further provided compelling evidence with enhanced cytotoxicity and low IC50 in SKOV3 cells. Therefore protamine sulphate coated microspheres may potentially be used for sustained delivery of *rINF-α-2b and warrants in depth in vivo study to scale up the technology for clinical intervention.

Ключевые слова: Microparticles, sustained release, anti-cancer, Interferones, ovarian cancer